The [[side effect]]s of flutamide are [[sex]]-dependent. In men, a variety of side effects related to [[androgen deprivation]] may occur, the most common being [[gynecomastia]] and [[breast tenderness]]<ref name="FaridaFaiza2013">{{cite journal|last1=Farida|first1=Chentli|last2=Faiza|first2=Belhimer|title=Severe gynecomastia due to anti androgens intake: A case report and literature review|journal=Indian Journal of Endocrinology and Metabolism|volume=17|issue=4|year=2013|pages=730|issn=2230-8210|doi=10.4103/2230-8210.113770}}</ref> The vast majority (>90%) of cases of gynecomastia with NSAAs including flutamide are mild to moderate.<ref name="Gillatt2006">{{cite journal|last1=Gillatt|first1=David|title=Antiandrogen treatments in locally advanced prostate cancer: are they all the same?|journal=Journal of Cancer Research and Clinical Oncology|volume=132|issue=S1|year=2006|pages=17–26|issn=0171-5216|doi=10.1007/s00432-006-0133-5|quote=Unlike CPA, non-steroidal antiandrogens appear to be better tolerated than castration, allowing patients to maintain sexual activity, physical ability, and bone mineral density, but these agents have a higher incidence of gynecomastia and breast pain (mild to moderate in > 90% of cases).|pmid=16845534}}</ref><ref name="GoldspielKohler1990">{{cite journal | vauthors = Goldspiel BR, Kohler DR | title = Flutamide: An Antiandrogen for Advanced Prostate Cancer | journal = Ann Pharmacother | volume = 24 | issue = 6 | pages = 616–623 | year = 1990 | pmid = 2193461 | doi = 10.1177/106002809002400612 | url = | quote = [...] They [in patients treated with flutamide] observed mild gynecomastia in 30 patients (57 percent), moderate gynecomastia in 19 (36 percent), and massive gynecomastia in 4 patients (8 percent). Complaints of nipple and areolar tenderness were noted in 50/53 patients (94 per- cent)." Airhart et al. reported that 42 percent of patients receiving flutamide 750 mg/d or 1500 mg/d developed gynecomastia within 12 weeks of starting treatment with an apparent direct correlation between the dose of flutamide administered and the severity of gynecomastia.25 In another study, two of five evaluable patients developed moderate gynecomastia with mild tenderness at four and eight weeks after starting flutamide 750 mg/d. Patients with preexisting gynecomastia as a result of previous endocrine therapy with estrogens sustained no worsening of their gynecomastia and may have improved symptomatically." Keating et al."}}</ref><ref name="Pratt1994">{{cite book|author=William B. Pratt|title=The Anticancer Drugs|url=https://books.google.com/books?id=nPR1L4K5HuEC&pg=PA220|year=1994|publisher=Oxford University Press|isbn=978-0-19-506739-2|pages=219–220}}</ref> and others including [[hot flash]]es, [[muscle atrophy|decreased muscle mass]], [[osteoporosis|decreased bone mass]] and an associated increased risk of [[bone fracture|fracture]]s, [[depression (mood)|depression]],<ref name="MydloGodec2015" /> and [[sexual dysfunction]] including reduced [[libido]] and [[erectile dysfunction]].<ref name="Lehne2013">{{cite book|author=Richard A. Lehne|title=Pharmacology for Nursing Care|url=https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297|year=2013|publisher=Elsevier Health Sciences|isbn=1-4377-3582-7|pages=1297–}}</ref> In women, flutamide is, generally, relatively well-tolerated, and does not interfere with [[ovulation]].<ref name="Azziz2007">{{cite book|author=Ricardo Azziz|title=Androgen Excess Disorders in Women|url=https://books.google.com/books?id=Ch-BsGAOtucC&pg=PA384|date=8 November 2007|publisher=Springer Science & Business Media|isbn=978-1-59745-179-6|pages=384–}}</ref> The only common side effect reported with flutamide in women is [[dry skin]] (75%), which is attributable to diminished androgen-mediated sebum production.<ref name="Publishers1999">{{cite book|author=Bentham Science Publishers|title=Current Pharmaceutical Design|url=https://books.google.com/books?id=9rfNZL6oEO0C&pg=PA712|date=September 1999|publisher=Bentham Science Publishers|pages=712–716|quote=Latest studies suggest that [flutamide] also reduces adrenal and ovarian androgen synthesis [58,59]. [...] No alteration in the hormone levels has been observed in patients treated with flutamide for 6 or 12 months [61,62]. However in other studies flutamide decreased circulating concentrations of DHEAS as well as androstenedione, total testosterone and 3a-androstanediol glucuronide, in young women with PCOS [41,59]. These effects may be due to inhibition of adrenal 17-20 lyase [17,63]. Although there was no effect on gonadotropin response to GnRH, basal levels of FSH showed a rise associated with a small fall of LH [64].}}</ref> General side effects that may occur in either sex include [[dizziness]], [[anorexia]], [[gastrointestinal]] side effects such as [[nausea]], [[vomiting]], and [[diarrhea]], a [[Urine#Color|greenish-bluish discoloration]] of the [[urine]],<ref name="Publishers1999" /> and [[hepatic]] changes.<ref name="MydloGodec2015" /><ref name="Lehne2013" /><ref name="RobertsSnyder1996">{{cite book|author1=Jay Roberts|author2=David L. Snyder|author3=Eitan Friedman|title=Handbook of Pharmacology on Aging|url=https://books.google.com/books?id=xVIJOFh5mfMC&pg=PA334|date=14 August 1996|publisher=CRC Press|isbn=978-0-8493-8306-9|pages=334–}}</ref> Because flutamide is a pure antiandrogen, unlike [[steroid]]al antiandrogens like [[cyproterone acetate]] and [[megestrol acetate]] (which additionally possess [[progestogen]]ic activity), it does not appear to have a risk of [[cardiovascular]] side effects (e.g., [[thromboembolism]]) or [[Water retention (medicine)|fluid retention]].<ref name="Pratt1994" /><ref name="MydloGodec2015" /><ref name="DenisGriffiths1999">{{cite book|author1=Louis J Denis|author2=Keith Griffiths|author3=Amir V Kaisary |author4=Gerald P Murphy|title=Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment|url=https://books.google.com/books?id=GreZlojD-tYC&pg=PA280|date=1 March 1999|publisher=CRC Press|isbn=978-1-85317-422-3|pages=279–280}}</ref>

 


 
[[Tamoxifen]], a [[selective estrogen receptor modulator]] (SERM) with predominantly [[antiestrogen]]ic actions, can counteract flutamide-induced gynecomastia and breast pain in men.

 

